Edgar Filing: NEKTAR THERAPEUTICS - Form 4

	IERAPEUTIC	S									
Form 4 September 23	2016										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB APPROVAL		
	Check this box if no longer subject to Section 16. Form 4 or					Number:	3235-0287 January 31,				
subject to Section 16						Expires: Estimated a burden hou response	2005 average Irs per				
obligation may contri <i>See</i> Instruct 1(b).	s Section 17	7(a) of the 1	Public Ut	ility Hol		ipany	Act o	f 1935 or Sectio	'n		
(Print or Type R	esponses)										
Krivulka Joseph J _{Sy}			2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]				g	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date o (Month/I				- f Earliest Transaction Day/Year)				X Director Officer (give below)		6 Owner er (specify	
	(Street)	Street) 4. If Amendment, Date Original 6 Filed(Month/Day/Year) A				Applicable Line) _X_ Form filed by	X_ Form filed by One Reporting Person				
SAN FRAN	CISCO, CA 94	158						Form filed by M Person	More than One R	eporting	
(City)	(State)	(Zip)	Table	e I - Non-l	Derivative S	Securi	ties Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Execution any		Code (Instr. 8)	Disposed) (Instr. 3,	l (A) o l of (D 4 and (A) or) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock (1)	09/21/2016	(2)		A	V Amount 8,000	(D) A	Price \$ 0	58,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities D
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 19.15	09/21/2016		А	20,000	(3)	09/20/2024	Common Stock	20,000

er

Edgar Filing: NEKTAR THERAPEUTICS - Form 4

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Othe	
Krivulka Joseph J C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO, CA 94158	Х				
Signatures					
Mark A. Wilson,	0.4.6				

Mark A. Wilson,	09/23/2016		
Attorney-In-Fact	072572010		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.
- (2) This restricted stock unit award vests in full, one year following September 21, 2016.
- (3) This option vests in equal monthly installments over the one-year period beginning on September 30, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.